HRP20220361T1 - Postupak i sastav za liječenje očne hipertenzije i glaukoma - Google Patents

Postupak i sastav za liječenje očne hipertenzije i glaukoma Download PDF

Info

Publication number
HRP20220361T1
HRP20220361T1 HRP20220361TT HRP20220361T HRP20220361T1 HR P20220361 T1 HRP20220361 T1 HR P20220361T1 HR P20220361T T HRP20220361T T HR P20220361TT HR P20220361 T HRP20220361 T HR P20220361T HR P20220361 T1 HRP20220361 T1 HR P20220361T1
Authority
HR
Croatia
Prior art keywords
aqueous solution
ophthalmic aqueous
solution according
container
vol
Prior art date
Application number
HRP20220361TT
Other languages
English (en)
Croatian (hr)
Inventor
Timo Reunamaki
Pertti Pellinen
Olli Oksala
Kari Lehmussaari
Original Assignee
Santen Pharmaceutical Co., Ltd.
AGC Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20220361(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co., Ltd., AGC Inc. filed Critical Santen Pharmaceutical Co., Ltd.
Publication of HRP20220361T1 publication Critical patent/HRP20220361T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20220361TT 2008-05-30 2009-05-28 Postupak i sastav za liječenje očne hipertenzije i glaukoma HRP20220361T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma
EP20164602.3A EP3714877B1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
HRP20220361T1 true HRP20220361T1 (hr) 2022-05-13

Family

ID=39940592

Family Applications (4)

Application Number Title Priority Date Filing Date
HRP20220361TT HRP20220361T1 (hr) 2008-05-30 2009-05-28 Postupak i sastav za liječenje očne hipertenzije i glaukoma
HRP20140979AT HRP20140979T1 (hr) 2008-05-30 2009-05-28 Postupak i sastav za lijeäśenje okularne hipertenzije i glaukoma
HRP20170769TT HRP20170769T1 (hr) 2008-05-30 2017-05-23 Postupak i pripravak za liječenje očne hipertenzije i glaukoma
HRP20200998TT HRP20200998T1 (hr) 2008-05-30 2020-06-24 Postupak i sastav za liječenje okularne hipertenzije i glaukoma

Family Applications After (3)

Application Number Title Priority Date Filing Date
HRP20140979AT HRP20140979T1 (hr) 2008-05-30 2009-05-28 Postupak i sastav za lijeäśenje okularne hipertenzije i glaukoma
HRP20170769TT HRP20170769T1 (hr) 2008-05-30 2017-05-23 Postupak i pripravak za liječenje očne hipertenzije i glaukoma
HRP20200998TT HRP20200998T1 (hr) 2008-05-30 2020-06-24 Postupak i sastav za liječenje okularne hipertenzije i glaukoma

Country Status (27)

Country Link
US (3) US9999593B2 (enExample)
EP (8) EP2127638A1 (enExample)
JP (9) JP2011521943A (enExample)
KR (5) KR101820816B1 (enExample)
CN (1) CN102083413B (enExample)
AR (2) AR071937A1 (enExample)
AU (1) AU2009252210C1 (enExample)
BR (1) BRPI0913109B8 (enExample)
CA (2) CA2965185A1 (enExample)
CY (2) CY1115565T1 (enExample)
DK (4) DK3714877T3 (enExample)
EA (1) EA023661B1 (enExample)
ES (6) ES2808050T3 (enExample)
GE (1) GEP20156220B (enExample)
HR (4) HRP20220361T1 (enExample)
HU (3) HUE058079T2 (enExample)
JO (1) JO3039B1 (enExample)
LT (3) LT2772249T (enExample)
MX (1) MX2010012987A (enExample)
MY (1) MY159463A (enExample)
PL (4) PL3714877T3 (enExample)
PT (4) PT2772249T (enExample)
SG (1) SG191628A1 (enExample)
SI (4) SI3714877T1 (enExample)
TW (1) TWI432202B (enExample)
UA (1) UA102257C2 (enExample)
WO (1) WO2009145356A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US10154923B2 (en) * 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
US9061034B2 (en) * 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
EP3431074B1 (en) * 2010-07-29 2022-01-19 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US20130245124A1 (en) * 2010-07-29 2013-09-19 Allergan, Inc. Preservative free bimatoprost solutions
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
ES2616089T3 (es) 2010-09-21 2017-06-09 S & V Technologies Gmbh Composición cosmética
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
JP2014510709A (ja) * 2011-04-12 2014-05-01 株式会社アールテック・ウエノ 眼科用水性組成物
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
HRP20230559T1 (hr) * 2012-08-24 2023-09-15 Sun Pharmaceutical Industries Limited Oftalmička formulacija polioksil lipida ili polioksil masne kiseline i tretman očnih stanja
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
WO2015106068A1 (en) 2014-01-10 2015-07-16 Manistee Partners Llc Treatment of migraines
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
ES2747302T3 (es) 2015-06-09 2020-03-10 Medproject Pharma Entw Und Vertriebsgesellschaft Mbh Gel oftálmico de bimatoprost aplicable en gotas
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
CA3004587A1 (en) * 2015-11-06 2017-05-11 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
ES2974821T3 (es) 2015-11-10 2024-07-01 Sun Pharmaceutical Ind Ltd Formulaciones tópicas y usos de las mismas
DK3423076T3 (da) 2016-02-29 2024-07-08 Sun Pharmaceutical Ind Ltd Topisk cyclosporinholdige formuleringer og anvendelser deraf
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
JP7165123B2 (ja) * 2017-03-27 2022-11-02 興和株式会社 医薬製剤
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
EP3643297A4 (en) 2017-06-22 2021-03-17 Yonsung Fine Chemical Co., Ltd. OPHTHALMIC COMPOSITION FOR THE TREATMENT OF GLAUCOMA
EP3730138B1 (en) * 2017-12-21 2024-02-14 Santen Pharmaceutical Co., Ltd. Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension
EP3820445A1 (en) 2018-07-09 2021-05-19 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic dispensing device
JP7599838B2 (ja) * 2019-04-10 2024-12-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性医薬組成物
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
CN116687842A (zh) * 2022-02-28 2023-09-05 山东新时代药业有限公司 一种拉坦前列素滴眼液及其制备方法
JPWO2023182480A1 (enExample) * 2022-03-25 2023-09-28
CN119384280A (zh) * 2022-06-16 2025-01-28 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
WO2024203727A1 (ja) * 2023-03-24 2024-10-03 株式会社坪田ラボ 水性組成物
CN121057582A (zh) * 2023-05-11 2025-12-02 特一华制药株式会社 抑制了前列腺素F2α衍生物的含有率降低的产品
JP7757564B1 (ja) * 2024-06-28 2025-10-21 東亜薬品株式会社 水性組成物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
ATE76750T1 (de) 1987-04-03 1992-06-15 Univ Columbia Anwendung eines prostaglandins in mischung mit einem adrenergischen blocker zur verminderung des augen-innendruckes.
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU704938B2 (en) * 1995-11-17 1999-05-06 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
DE69714274T3 (de) 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
EP0944530A1 (en) 1996-12-09 1999-09-29 Bausch & Lomb Incorporated Single-use flexible container
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
ATE326972T1 (de) 1997-10-13 2006-06-15 R Tech Ueno Ltd Heilende zusammensetzung für intraokulare hypertension oder glaukom
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
DE69922916T2 (de) * 1998-07-14 2005-06-09 Alcon Manufacturing Ltd., Fort Worth Polypropylenbasierte behälter für prostaglandin-enthaltende produkte
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US6486208B1 (en) 1998-09-25 2002-11-26 Alcon Laboratories, Inc. Sustained release, and comfortable opthalmic composition and method for ocular therapy
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
PL350924A1 (en) 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
ATE324910T1 (de) 2000-06-19 2006-06-15 Santen Pharmaceutical Co Ltd Aseptische mittel
JP3876355B2 (ja) 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
DK1321144T3 (da) * 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
TW586946B (en) 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
WO2004006826A1 (ja) 2002-07-16 2004-01-22 Senju Pharmaceutical Co., Ltd. 薬液容器及びその製造方法
KR101253941B1 (ko) 2002-09-09 2013-04-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
WO2005011704A1 (ja) 2003-07-31 2005-02-10 Santen Pharmaceutical Co., Ltd. プロスタグランジン含有製品
US20050287325A1 (en) 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
ES2314354T3 (es) 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
WO2006058139A2 (en) 2004-11-24 2006-06-01 Holopack International Corp. Dispensing container with flow control system
WO2006062184A1 (ja) 2004-12-09 2006-06-15 Santen Pharmaceutical Co., Ltd. 分子内にフッ素原子を有するプロスタグランジン含有製品
ES2386148T3 (es) 2004-12-24 2012-08-10 Santen Pharmaceutical Co., Ltd. Productos que contienen un derivado de prostaglandina F2 alfa
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
CA2615108A1 (en) 2005-07-13 2007-01-18 Santen Pharmaceutical Co., Ltd. Preservative composition for ophthalmic use
EP1916002B1 (en) 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
EP1937212B1 (en) 2005-10-10 2010-09-01 Novagali Pharma S.A. Ophthalmic emulsions containing prostaglandins
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
ES2808050T3 (es) 2021-02-25
US20210059931A1 (en) 2021-03-04
EA201071413A1 (ru) 2011-06-30
HUE033103T2 (en) 2017-11-28
JP2011521943A (ja) 2011-07-28
KR20180008905A (ko) 2018-01-24
JP6889789B2 (ja) 2021-06-18
EP4035656B1 (en) 2023-11-22
LT2772249T (lt) 2017-09-11
HRP20200998T1 (hr) 2020-10-16
AU2009252210C1 (en) 2016-04-14
CA2724194A1 (en) 2009-12-03
BRPI0913109B1 (pt) 2019-10-22
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
EP4289446B1 (en) 2025-02-12
CY1115565T1 (el) 2017-01-04
PL3205334T3 (pl) 2020-11-02
DK2306977T3 (da) 2014-09-15
PL2306977T3 (pl) 2015-01-30
AR071937A1 (es) 2010-07-28
BRPI0913109B8 (pt) 2021-05-25
JP6356868B2 (ja) 2018-07-11
EP2306977B1 (en) 2014-08-13
KR101650006B1 (ko) 2016-08-22
EP3205334B1 (en) 2020-04-29
TWI432202B (zh) 2014-04-01
JP7520285B2 (ja) 2024-07-23
PT3205334T (pt) 2020-07-31
JP7265584B2 (ja) 2023-04-26
ES2907982T3 (es) 2022-04-27
JP2018154656A (ja) 2018-10-04
EP2772249A1 (en) 2014-09-03
KR20110011707A (ko) 2011-02-08
EP2306977A1 (en) 2011-04-13
EP3205334A1 (en) 2017-08-16
JO3039B1 (ar) 2016-09-05
US20180289618A1 (en) 2018-10-11
JP6649992B2 (ja) 2020-02-19
EP4512424A3 (en) 2025-03-05
WO2009145356A1 (en) 2009-12-03
PT2306977E (pt) 2014-09-22
LT3714877T (lt) 2022-04-11
EP2127638A1 (en) 2009-12-02
SG191628A1 (en) 2013-07-31
JP6148317B2 (ja) 2017-06-14
GEP20156220B (en) 2015-01-26
PL2772249T3 (pl) 2017-10-31
ES2495316T3 (es) 2014-09-17
JP2023085558A (ja) 2023-06-20
MY159463A (en) 2017-01-13
HRP20170769T1 (hr) 2017-08-11
ES2968837T3 (es) 2024-05-14
EP4289446A3 (en) 2024-01-10
US9999593B2 (en) 2018-06-19
KR102246598B1 (ko) 2021-04-30
AU2009252210A1 (en) 2009-12-03
DK2772249T3 (en) 2017-07-17
ES2627837T3 (es) 2017-07-31
PT3714877T (pt) 2022-03-10
CN102083413B (zh) 2013-11-06
JP2021120412A (ja) 2021-08-19
CN102083413A (zh) 2011-06-01
LT3205334T (lt) 2020-09-25
KR101820816B1 (ko) 2018-01-22
EP4035656A1 (en) 2022-08-03
HUE058079T2 (hu) 2022-06-28
KR101988642B1 (ko) 2019-06-12
DK3714877T3 (da) 2022-02-14
TW201000104A (en) 2010-01-01
KR102114401B1 (ko) 2020-05-25
EP3714877A1 (en) 2020-09-30
DK3205334T3 (da) 2020-07-13
EP2772249B1 (en) 2017-05-03
ES2627837T8 (es) 2018-02-26
EP3714877B1 (en) 2022-01-26
EP4512424A2 (en) 2025-02-26
JP2014133765A (ja) 2014-07-24
EP4289446A2 (en) 2023-12-13
JP2017178957A (ja) 2017-10-05
BRPI0913109A2 (pt) 2017-06-20
AR120961A2 (es) 2022-04-06
JP2016065095A (ja) 2016-04-28
JP2024079852A (ja) 2024-06-11
CY1120351T1 (el) 2019-07-10
HRP20140979T1 (hr) 2014-11-21
PL3714877T3 (pl) 2022-05-16
EA023661B1 (ru) 2016-06-30
SI2772249T1 (sl) 2017-08-31
ES3014089T3 (en) 2025-04-16
PT2772249T (pt) 2017-08-08
KR20160102319A (ko) 2016-08-29
SI3714877T1 (sl) 2022-05-31
CA2965185A1 (en) 2009-12-03
US10864159B2 (en) 2020-12-15
MX2010012987A (es) 2011-02-24
KR20200057801A (ko) 2020-05-26
CA2724194C (en) 2017-06-27
HUE049923T2 (hu) 2020-11-30
UA102257C2 (uk) 2013-06-25
AU2009252210B2 (en) 2014-10-16
US20110152264A1 (en) 2011-06-23
KR20190067272A (ko) 2019-06-14
JP2020073574A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
HRP20220361T1 (hr) Postupak i sastav za liječenje očne hipertenzije i glaukoma
JP6757435B2 (ja) 眼科用水性組成物
ES2638771T3 (es) Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
AR070824A1 (es) Suspensiones para inyeccion intravitrea de triamcinolona acetonido de baja viscosidad, altamente floculadas
AR069792A1 (es) Composicion agroquimica y metodo para preparar la misma
WO2009028495A1 (ja) 真菌性皮膚炎用剤
JP2016065095A5 (enExample)
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
GB2581656A (en) Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
AR081364A1 (es) Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
EA200700109A1 (ru) Способы лечения офтальмологических состояний (варианты)
EA201200762A1 (ru) Применение простагландинов f2-альфа и аналогов для заживления повреждений роговицы и конъюнктивы
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
JP2012520882A5 (enExample)
RU2248789C2 (ru) Офтальмическая композиция, содержащая кетотифен
JP2013535472A5 (enExample)
ITRM20090102U1 (it) Ialuvit preparato per la stabilizzazione del film lacrimale, la cicatrizzazione corneale e il ripristino del contenuto salino della lacrima e osmoprotezione.
RU2019139886A (ru) Терапевтическое средство против дисфункции мейбомиевых желез
CA2934453A1 (en) Compositions and methods for treatment of glaucoma
PE20061077A1 (es) Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina
JP2021107464A (ja) 眼科組成物
NZ596035A (en) METHOD AND COMPOSITION FOR TREATING MACULAR DEGENERATION using 15-keto-prostaglandin such as 13,14-dihydro-15-keto-20-ethyl-prostagladin F2-alpha isopropyl ester
KR102288699B1 (ko) 수성 의약 조성물
ES2321875T3 (es) Preparacion oftalmica esteril,multifase, sin emulsionante aplicable en gotas.